

Epigenetic Silencing of Cellular Retinol-Binding Proteins in Nasopharyngeal Carcinoma

Joseph Kwong*, Kwok-Wai Lo*, Lillian Shuk-Nga Chow*, Ka-Fai To*, Kwong-Wai Choy[†], Franky Leung Chan[‡], Samuel C. Mok[§] and Dolly P. Huang

Departments of *Anatomical and Cellular Pathology, [†]Ophthalmology and Visual Sciences, and [‡]Anatomy The Chinese University of Hong Kong, Hong Kong, SAR, China; [§]Laboratory of Gynecologic Oncology, Division of Gynecologic Oncology, Department of Obstetrics, Gynecologic, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

Abstract

Aberrant retinoid signaling in human cancers is extending from the nucleus to the cytoplasm. Recently, we have demonstrated frequent epigenetic inactivation of a retinoic acid receptor (RAR), *RARβ2*, in nasopharyngeal carcinoma (NPC). To further explore targets contributing to aberrant retinoid signaling in NPC, the expression of cellular retinol-binding proteins (CRBPs), cellular retinoic acid-binding proteins (CRABPs), RARs, and retinoid X receptors (RXRs) was examined. Apart from *RARβ2*, transcriptional silencing of two CRBPs, *CRBPI* and *CRBPIV*, was observed in NPC cell lines and xenografts. Hypermethylation of *CRBPI* and *CRBPIV* CpG islands was found to be closely correlated with the loss of expression. Treatment with the DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, resulted in reexpression of *CRBPI* and *CRBPIV* gene expression in NPC cell lines. Both *CRBPI* and *CRBPIV* hypermethylations were also observed in 43/48 (87.8%) and 26/48 (54.2%) primary NPC tumors, respectively. Here, we reported for the first time that *CRBPIV* was transcriptionally inactivated by promoter hypermethylation in human cancer. Simultaneous methylation of *CRBPI*, *CRBPIV*, and *RARβ2* was commonly found in NPC primary tumors. Our findings implied that epigenetic disruption of the CRBPs, *CRBPI* and *CRBPIV*, is important in NPC tumorigenesis and may contribute to the loss of retinoic acid responsiveness in cancer.

Neoplasia (2005) 7, 67–74

Keywords: *CRBPIV*, *CRBPI*, retinoid, hypermethylation, nasopharyngeal carcinoma.

Introduction

Retinol, or vitamin A, is indispensable for embryonic development, growth, vision, and survival of vertebrates [1]. The vitamin A metabolite, retinoic acid, regulates multiple biologic processes, including cell proliferation and differentiation, by modulating the rate of transcription of numerous target genes. The effects of retinoic acid are mediated by at least two types of proteins: cellular retinoid-binding

proteins and nuclear retinoid receptors. The cellular retinoid-binding proteins, including CRBPs and cellular retinoic acid-binding proteins (CRABPs), belong to a family of cytosolic proteins binding small hydrophobic ligands [2]. CRBPs are proposed to facilitate the formation of retinol esters for storage or conversion of retinol to retinoic acid through a retinal intermediate. These proteins may also participate in the entry of retinol into the cell [3]. The function of CRABPs is to protect retinoids *in vivo* from other cellular proteins, transform bound retinoid into specific biologic compounds, and modulate the concentration of free retinoic acid available to nuclear retinoid receptors [4]. Retinoid receptors function as ligand-inducible transcription factors. Two subtypes of retinoid receptor exist, namely, retinoic acid receptors (RARs) and retinoid X receptors (RXRs). RARs are activated by all-*trans*-retinoic acid, and 9-*cis*-retinoic acid activates both RARs and RXRs. RARs form heterodimers with RXRs, which regulate transcription by binding at the retinoic acid response elements (RAREs) on the promoter regions of various target genes [5].

Aberrant retinoid signaling in cancer has been firstly highlighted by the leukemogenic role of the promyelocytic leukemia-RAR α fusion protein [6]. Frequent reduced expression and aberrant promoter methylation of *RARβ2* in solid cancers have also been reported [7–10]. Aside from retinoid receptors, transcriptional silencing of a cellular retinoid-binding protein, *CRBPI*, by promoter hypermethylation is common in human cancers [11]. In NPC, only mild growth inhibition was observed when treating with 13-*cis* retinoic acid, although retinoid was used in chemotherapy and chemoprevention of head and neck cancer [12]. These data implied that defects in retinoid signaling may occur in NPC. Our previous study has demonstrated that transcription silencing of *RARβ2* by promoter hypermethylation is common in both NPC cell lines and primary tumors [13]. To explore targets contributing to aberrant

Abbreviations: CRBP, cellular retinol-binding protein; CRABP, cellular retinoic acid-binding protein; RAR, retinoic acid receptor; RXR, retinoid X receptor

Address all correspondence to: Kwok-Wai Lo, Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, 5/F, Cancer Center, Prince of Wales Hospital, Shatin, NT, Hong Kong, SAR, China. E-mail: kwlo@cuhk.edu.hk

Received 4 June 2004; Revised 7 July 2004; Accepted 9 July 2004.

Copyright © 2005 Neoplasia Press, Inc. All rights reserved 1522-8002/05/\$25.00
DOI 10.1593/neo.04370

retinoid signaling in NPC, we investigated the expression of retinoid signaling molecules (*CRBPs*, *CRABPs*, *RARs*, and *RXRs*) comprehensively. Besides *RAR β 2*, we have firstly discovered the silencing of two cellular retinol-binding proteins (*CRBPs*), *CRBPI* and *CRBP IV* , by promoter hypermethylation in NPC cells. Our findings demonstrated that hypermethylation of *CRBPs* is common in NPC and may contribute to the disruption of retinoid signaling in this cancer.

Materials and Methods

Cell Lines, Xenografts, and Primary Tumors

Five NPC cell lines (C666-1, CNE1, CNE2, HK1, and HONE1), three xenografts (X2117, X666, and XNPC8), an immortalized nasopharyngeal epithelial cell line (NP69), and two samples of normal nasopharyngeal epithelial outgrowth cultures (NP1 and NP2) were included in our study [14,15]. The NPC cell lines were maintained in RPMI 1640 medium supplemented with 10% FBS, whereas NP69 was grown in keratinocyte serum-free medium (Invitrogen, Carlsbad, CA). Forty-nine cases of archived paraffin-embedded primary NPC tumors were retrieved from the pathology bank of the Department of Anatomical and Cellular Pathology at The Chinese University of Hong Kong (Hong Kong, SAR, China). The neoplastic cells were isolated from each tumor sample by microdissection and subjected to DNA extraction as described previously [16]. The histologic diagnoses of the specimens were confirmed by a pathologist. All of these tumors were classified as undifferentiated carcinomas. The male-to-female ratio of patients was 4.8:1. The age range was 36 to 68 years (mean 52 years). The clinical disease stage of patients is from stages II to IV (UICC staging classification).

Reverse Transcription Polymerase Chain Reaction (RT-PCR)

The mRNA expression of *CRBP* (*CRBPI*, *CRBP II* , *CRBP III* , and *CRBP IV*), *CRABP* (*CRABP I* and *CRABP II*), *RAR* (*RAR α* , *RAR β 2*, and *RAR γ*), and *RXR* (*RXR α* , *RXR β* , and *RXR γ*) genes in NPC cell lines, xenografts, and pool samples from normal nasopharyngeal epithelia (normal NP) was examined by RT-PCR analysis. Total RNA of nasopharyngeal samples was isolated using TRIZOL reagent (Invitrogen) according to the manufacturer's protocol. Two micrograms of total RNA from each sample was subjected to cDNA synthesis using Superscript II reverse transcriptase (Invitrogen). The primers and conditions for RT-PCR analysis were listed in Table 1. The transcript of *GAPDH* was amplified as control.

Real-Time RT-PCR

The expression of *CRBPI*, *CRBP IV* , and *RAR β 2* was quantitatively examined in nasopharyngeal epithelial cells by real-time RT-PCR analysis. By using the SYBR Green RT-PCR Kit (Applied Biosystems, Foster City, CA), PCR products were stained with SYBR Green and analyzed using an I-cycler (Bio-Rad, Hercules, CA). The PCR primers and conditions were listed in Table 1. All reactions were per-

formed in triplicate. Relative mRNA of the target gene of each NPC line was normalized with β -actin and calculated using the $2^{-[\Delta\Delta C(T)]}$ method, which compares the mRNA amount of each sample to that of normal NP.

Bisulfite Sequencing

To investigate the *de novo* methylation pattern of the 5' CpG island of *CRBPI* and *CRBP IV* in NPC, five NPC cell lines, three xenografts, and two normal nasopharyngeal epithelial cell growths (NP1 and NP2) were subjected to bisulfite sequencing. Genomic DNA were modified by bisulfite treatment using the CpGenome DNA Modification Kit (Intergen, New York, NY). For the *CRBPI* and *CRBP IV* genes, the DNA sequence of the putative promoter and exon 1 were obtained from the UCSC Genome Browser, and the CpG islands of these genes were then identified. The criteria of a 5' CpG island are: GC content > 60%, ratio of CpG to GpC > 0.6, and minimum length of 200 bp. The PCR primers are listed in Figure 2. For bisulfite sequencing, PCR amplification was performed on 100 ng of bisulfite-modified genomic DNA. The amplified fragments were cloned, and 8 to 10 clones of each sample were sequenced with a Big Dye Terminator Reaction Mix and analyzed by a ABI 3100 Genetic Analyzer (Applied Biosystems).

Methylation-Specific PCR (MSP)

The promoter methylation status of *CRBPI*, *CRBP IV* , and *RAR β 2* in the primary tumors was investigated by MSP as described previously [17]. Genomic DNA of the microdissected specimens were modified by bisulfite treatment. Primer sequences for both methylated and unmethylated alleles of the genes were shown in Figure 2. One microliter of bisulfite-modified DNA from the samples was subjected to PCR amplification. *In vitro* methylated DNA (IVD) (Intergen) served as a control for methylated sequences, whereas DNA from peripheral blood lymphocytes (PBLs) served as a control for unmethylated sequences. All MSP reactions were duplicated. Twenty-five microliters of PCR products was loaded onto a 10% nondenaturing polyacrylamide gel, stained with ethidium bromide, and visualized under UV illumination.

5-Aza-2'-deoxycytidine Treatment

To examine the correlation of promoter hypermethylation and expression of *RAR β 2*, *CRBPI*, and *CRBP IV* genes, NPC cell lines were subject to 5-aza-2'-deoxycytidine treatment. Cells were plated and incubated for 4 days with 0, 1, 3, and 5 μ M 5-aza-2'-deoxycytidine (Sigma Chemical Co., St. Louis, MO). The medium and the drug were replaced every 24 hours, and cells were harvested for total RNA and DNA extraction after 4 days.

Results

Aberrant Expression of *CRBPI*, *CRBP IV* , *CRABP I* , and *RAR β 2* in NPC

In this study, we have comprehensively examined the transcription of the *CRBP* (*CRBPI*, *CRBP II* , *CRBP III* , and

Table 1. PCR Primer Sequences and Conditions for RT-PCR and Real-Time Quantitative RT-PCR.

Genes	Sequences	Product Size (bp)	Annealing (°C)	Cycles
<i>RT-PCR</i>				
<i>CRBPI</i>	Forward: 5'-AAACTGGCTCCAGTCACTCC-3' Reverse: 5'-CAGGTCACCTTTATTGGCATGG-3'	610	65	35
<i>CRBP1I</i>	Forward: 5'-CAGAATGGAACCTGGGAGAT-3' Reverse: 5'-AGGTCAGCTCCAGGTACAGC-3'	352	60	35
<i>CRBP1II</i>	Forward: 5'-CGGAGAGAAGCCAAGATCCC-3' Reverse: 5'-TGGGACGCCAGACCTTGACC-3'	239	67	35
<i>CRBP1V</i>	Forward: 5'-TCCACATCCAGCAGCAGAGCC-3' Reverse: 5'-GGACAGGTTTATTGAAGCTGAGC-3'	182	67	35
<i>CRABPI</i>	Forward: 5'-CCTTGCGAGCTCAGAGTGT-3' Reverse: 5'-TTTGAGACACGTCTAACCAGTTT-3'	721	62	35
<i>CRABPII</i>	Forward: 5'-CCAACTTCTCTGGCAACTGG-3' Reverse: 5'-TAGACCCTGGTGCACACAAC-3'	400	62	35
<i>RARα</i>	Forward: 5'-GTCTTTGCCTTCGCCAACCCAG-3' Reverse: 5'-GCCCTCTGAGTTCTCCAACA-3'	333	60	35
<i>RARβ2</i>	Forward: 5'-TGCAAGGGAGATCATGTTTG-3' Reverse: 5'-TTATTGCACGAGTGGTACTG-3'	1360	60	35
<i>RARγ</i>	Forward: 5'-TTCGAGATGCTGAGCCCTAGCTTCC-3' Reverse: 5'-CATGCCCACTTCAAAGCACTTCTGC-3'	351	62	35
<i>RXRα</i>	Forward: 5'-TTCTCCACCCAGGTGAAGTC-3' Reverse: 5'-GGGTGAAAAGCTGTTTGTGC-3'	805	62	35
<i>RXRβ</i>	Forward: 5'-CTTTCTCTCAGGGGCTTCTC-3' Reverse: 5'-ACCCCATGGAAGAAGTATG-3'	521	62	35
<i>RXRγ</i>	Forward: 5'-CAGGAAAGCACTACGGGTA-3' Reverse: 5'-GCTGTTCCGGATACTTCTGC-3'	798	62	35
<i>GAPDH</i>	Forward: 5'-TGAAGGTCGGAGTCAACGGATTGGT-3' Reverse: 5'-CATGTGGCCATGAGGTCCACCAC-3'	983	65	35
<i>Real-time QRT-PCR</i>				
<i>CRBPI</i>	Forward: 5'-GGGAAGGAGTTTGAGGAGGA-3' Reverse: 5'-TTCTCACCTTCTGCACACA-3'	105	60	
<i>CRBP1V</i>	Forward: 5'-TCCACATCCAGCAGCAGAGCC-3' Reverse: 5'-GGACAGGTTTATTGAAGTCTGAGC-3'	182	65	
<i>CRABPI</i>	Forward: 5'-AGGTCCGAGAAGGCTTTGAG-3' Reverse: 5'-AGAAGAGTTTGCCTGCAGTG-3'	104	60	
<i>RARβ2</i>	Forward: 5'-CAGGAGAAAGCTCTCAAAGCA-3' Reverse: 5'-CTTGGGACGAGTTCCCTCAGA-3'	117	60	
<i>β-Actin</i>	Forward: 5'-CGCGAGAAGATGACCCAGAT-3' Reverse: 5'-GTACGGCCAGAGGCGTACAG-3'	98	60	

CRBP1V), *CRABP* (*CRABPI* and *CRABPII*), *RAR* (*RAR α* , *RAR β 2*, and *RAR γ*) and *RXR* (*RXR α* , *RXR β* , and *RXR γ*) genes in NPC cell lines, xenografts, and pool samples from normal nasopharyngeal epithelia (normal NP) by RT-PCR analysis. Among the 12 genes examined, *CRBP1I* and *CRABPI* showed no expression in normal nasopharyngeal epithelial cells. The finding suggested that these two genes are not involved in the retinoid signaling in this cell type. We have also found the expression of seven genes (*CRBP1II*, *CRABPII*, *RAR α* , *RAR γ* , *RXR α* , *RXR β* , and *RXR γ*) in all NPC samples as well as normal NP. As shown in Figure 1A, only the expression of three retinoid signaling molecules, including *RAR β 2*, *CRBPI*, and *CRBP1V*, was lost in most of the NPC cell lines and xenografts. Consistent with our previous report, expression of *RAR β 2* was lost in 60% of NPC cell lines (3/5; C666-1, CNE2, and HK1) and an NPC xenograft (X666). The complete loss of *RAR β 2* expression in these NPC samples has also been confirmed by real-time RT-PCR analysis. The quantitative analysis has further demonstrated a dramatic downregulation of *RAR β 2* expression in the other two NPC cell lines, CNE1 and HONE1 (Figure 1B).

The *CRBPI* transcripts were found to be lost in 5/5 (100%) NPC cell lines (C666-1, CNE1, CNE2, HK1, and HONE1) and 2/3 xenografts (2/3; X666 and XNPC8) by both conventional and quantitative RT-PCR analysis. Downregulation of *CRBPI* transcript (35-fold) was also detected in the xenograft X2117 (Figure 1B). For the *CRBP1V* gene, no expression has also been detected in all NPC cell lines and 2/3 xenografts (X2117 and X666), whereas downregulation of the gene was observed in the xenograft XNPC8 (Figure 1B). Our results demonstrated that loss of *CRBPI* and *CRBP1V* expression was frequently detected in NPC cell lines and xenografts.

Methylation Status of CRBPI and CRBP1V Promoters in NPC Cell Lines and Xenografts

Aberrant promoter hypermethylation is closely related to the loss of gene expression of cancer-related genes in human cancer. To assess whether the loss of *CRBPI* and *CRBP1V* expression in NPC was correlated with promoter hypermethylation, the methylation status of the 5' CpG island of the genes was determined by bisulfite genomic sequencing.




Figure 1. Detection of *CRBP I*, *CRBP IV*, and *RARβ2* expression in NPC cell lines, xenografts, and normal nasopharyngeal epithelia (NP) by (A) RT-PCR analysis and (B) real-time RT-PCR analysis.

For *CRBP I* gene, a 414-bp fragment from the 5' CpG island was amplified and a total of 38 CpG dinucleotides was investigated (Figure 2A). Dense methylation was observed in seven NPC samples (C666-1, CNE1, CNE2, HK1, HONE1, X666, and XNPC8) without *CRBP I* expression. Partial methylation was found in a xenograft (X2117) that showed downregulation of *CRBP I* expression. No aberrant methylation was found in the two normal nasopharyngeal epithelial samples (NP1 and NP2). For *CRBP IV*, 29 CpG dinucleotides within its 5'-promoter region were investigated (Figure 2B). The 5' CpG island of *CRBP IV*, especially the CpG sites within exon 1, exclusively methylated in all seven NPC lines (C666-1, CNE1, CNE2, HK1, HONE1, X2117, and X666) incapable of expressing *CRBP IV*. No methylation was observed in *CRBP IV*-expressing NPC xenograft (XNPC8) and normal nasopharyngeal epithelial cells (NP1 and NP2). The results suggest a strong correlation of transcriptional silencing of *CRBP I* and *CRBP IV* with dense methylation of their promoters.

In addition to *CRBP I* and *CRBP IV*, we also examined the methylation pattern of *RARβ2* promoter as described previously [9,10,13]. Dense methylation of *RARβ2* promoter was found in five NPC cell lines (C666-1, CNE1, CNE2, HK1, and HONE1) and an NPC xenograft (X666), which showed either absent or dramatic reduction in *RARβ2* expression. However, no methylation was found in XNPC8, although it showed a reduced expression of *RARβ2*. Methylated sequences were rarely found in *RARβ2*-expressing samples, including an NPC xenograft (X2117) and normal nasopharyngeal epithelial outgrowths (NP1 and NP2). The find-

ings confirmed that promoter hypermethylation is the major mechanism for *RARβ2* inactivation in NPC [13].

Reactivating *CRBP I* and *CRBP IV* Expression after 5-Aza-2'-deoxycytidine Treatment

Because promoter methylation status is intimately associated with *CRBP I* and *CRBP IV*, we sought to ask whether demethylation of the *CRBP I* and *CRBP IV* promoters is required for restoration of their expression. For this purpose, we treated the NPC cell line HK1, which showed transcriptional silencing and promoter hypermethylation of *CRBP I* and *RARβ2* with the demethylation agent, 5-aza-2'-deoxycytidine. After treatment, unmethylated alleles of *CRBP I* and *RARβ2* were detected by MSP analysis, whereas re-expression of these genes was observed. (Figure 3, A and C). Reexpression and demethylation of the *CRBP IV* gene were also detected in the 5-aza-2'-deoxycytidine-treated NPC cell line C666-1 in which dense methylation and transcriptional inactivation of *CRBP IV* were found (Figure 3B).

Promoter Hypermethylation of *CRBP I* and *CRBP IV* in Primary NPC Tumors

To assess the prevalence of promoter hypermethylation of *CRBP I* and *CRBP IV* in primary NPC tumors, we examined 49 primary NPC samples by MSP. The results of MSP analysis showed remarkable correlation with bisulfite genomic sequencing in cell lines and xenografts. Collectively, aberrant promoter hypermethylation of *CRBP I* and *CRBP IV* was found in 43/49 (87.8%) and 26/48 (54.2%) of primary

NPCs, respectively. We have correlated the methylated status of each of the genes with the stage of the NPC patient. No significant correlation between methylation of these genes and stage was found (data not shown). Forty-six samples (93.9%) showed aberrant methylation of either *CRBPI* or *CRBP1V*. The representative examples of MSP analysis of *CRBPI* and *CRBP1V* of NPC primary tumors are shown in Figure 4. Among 49 primary tumors examined, 23 (46.9%) cases showed promoter hypermethylation of both *CRBPI* and *CRBP1V* genes (Table 2). Taken together, our results demonstrated high frequencies of *CRBP* promoter hypermethylation in NPC cell lines, xenografts, and primary tumors.

To elucidate the relationship of promoter hypermethylation of *CRBPI*, *CRBP1V*, and *RARβ2*, the methylation status of *RARβ2* was also determined in the 49 primary tumors by MSP. Hypermethylation of *RARβ2* was detected in 37/47 (78.7%) of primary tumors. No significant correlation of *RARβ2* methylation and stage of patients was found. Similar

findings have also reported in our previous study [13]. Forty-seven primary tumors (95.9%) showed methylation of at least one of the *CRBPI*, *CRBP1V*, and *RARβ2* genes (Table 2). Promoter methylation of all three genes was found in 1/3 xenografts, 5/5 cell lines, and 21/49 (42.9%) primary tumors. The findings showed that the concurrent simultaneous inactivation of the *CRBPI*, *CRBP1V*, and *RARβ2* genes by hypermethylation is relatively common in NPC.

Discussion

In the present study, we have screened for aberrant expression of the components of the retinoic acid pathway (cellular retinoid-binding proteins and nuclear retinoid receptors) in NPC. In addition to the well-studied *RARβ2* gene, two retinoid signaling components, *CRBPI* and *CRBP1V*, were found to be common targets for epigenetic inactivation. A high frequency of *CRBPI* and *CRBP1V* promoter hypermethylation




Figure 2. Bisulfite sequencing of the *CRBPI*, *CRBP1V*, and *RARβ2* 5' CpG islands in NPC cell lines, xenografts, and normal nasopharyngeal epithelial outgrowths (NP1 and NP2). Each row represents an individual subclone. Open circles, unmethylated CpG sites; closed circles, methylated CpG sites. The nucleotide position of CpG sites (grey bar) is indicated at the top. The primer sequences of bisulfite sequencing and MSP analysis are listed at the bottom. RARE, retinoic acid responsive element.




Figure 3. (A) Reactivation of *CRBPI* expression in NPC cell line (HK1) treated with 5-aza-2'-deoxycytidine. Left panel: The reexpression of *CRBPI* in HK1 after 5-aza-2'-deoxycytidine treatment. Right panel: The methylation status of *CRBPI* promoter of HK1 cells after demethylation. MSP analysis demonstrated that the unmethylated sequence was detected in samples treated with 5-aza-2'-deoxycytidine. (B) Reexpression of *CRBPiV* and detection of unmethylated sequences in NPC cell line C666-1 treated with 5-aza-2'-deoxycytidine. (C) After 5-aza-2'-deoxycytidine treatment, *RARβ2* transcripts and unmethylated allele was detected in the NPC cell line HK1.

(88% and 54%, respectively) was detected in primary NPC tumors. The findings suggest that loss of *CRBPI* and *CRBPiV* expression is important in NPC development. Inac-

tivation of these *CRBP* genes may result in the loss of cellular retinoic acid homeostasis, inability to uptake natural retinol, and synthesis of retinoic acid.




Figure 4. Representative examples of MSP analysis of *CRBPI*, *CRBPiV*, and *RARβ2* in primary NPC tumors. The PCR products in lane m indicate the presence of methylated templates of the genes; the PCR products in lane u show the presence of unmethylated alleles. In vitro methylated DNA (IVD) and peripheral blood lymphocytes (PBLs) served as methylated and unmethylated controls, respectively. H_2O , negative control.

Table 2. Methylation of *RAR β* , *CRBPI*, and *CRBP IV* in Primary Tumors of NPC.

Promoter Methylation	Methylated Cases/Total Number	Percentage
<i>CRBP1</i>	43/49	87.8
<i>CRBPIV</i>	26/48	54.2
<i>RARβ</i>	37/47	78.7
<i>CRBPI</i> and <i>CRBPIV</i>	23/49	46.9
<i>RARβ</i> and <i>CRBPI</i>	34/49	69.4
<i>RARβ</i> and <i>CRBPIV</i>	23/49	46.9
<i>RARβ</i> , <i>CRBPI</i> , and <i>CRBPIV</i>	21/49	42.9
<i>CRBPI</i> or <i>CRBPIV</i>	46/49	93.9
<i>RARβ</i> or <i>CRBPI</i>	46/49	93.9
<i>RARβ</i> or <i>CRBPIV</i>	40/49	81.9
<i>RARβ</i> or <i>CRBPI</i> or <i>CRBPIV</i>	47/49	95.9

CRBPI is the most well-known retinoid-binding protein, and it is postulated to regulate the uptake and intracellular fate of retinol. This protein draws retinol from the bloodstream into cells, solubilizes retinol and retinal, and protects cells from membranolytic retinoid action [18]. Thus, loss of *CRBPI* would be expected to compromise retinol uptake, providing a growth advantage to cancer cells. Additionally, the absence of *CRBPI* may also compromise retinoic acid synthesis through the conversion of retinol to retinyl ester or retinoic acid [18,19]. This conversion includes several enzymatic reactions that probably function through recognition of retinoid-binding proteins [20]. In breast cancer, loss of *CRBPI* expression was as frequent in ductal carcinoma *in situ* as in invasive lesion, suggesting that it is a relatively early event in carcinogenesis [21]. A functional study has shown that downregulation of CRBP blocks differentiation and promotes the growth of SV40-transformed breast epithelial cells [22]. Recently, Esteller et al. [11] have also demonstrated that *CRBPI* was commonly silenced by promoter hypermethylation in various human malignancies, including lymphoma (60%), colon cancer (57%), gastric cancer (42%), liver cancer (30%), and breast cancer (19%). The extremely high incidence of *CRBPI* methylation (87.8%) suggested that the gene may play a role in NPC tumorigenesis though the disruption of the retinoid signaling pathway.

CRBP IV is newly identified and belongs to a clearly distinct CRBP superfamily with a relatively different mode of retinol-binding activity [23]. In this study, we have provided the first evidence that transcription silencing of *CRBP IV* by aberrant methylation is involved in the tumorigenesis of human cancers. The *CRBP IV* gene was not only frequently inactivated in NPC, our preliminary study also detected *CRBP IV* promoter hypermethylation in multiple human cancer cell lines, including colon cancer (2/5), prostatic cancer (2/5), and ovarian cancer (4/13) (personal observation). The findings implied that *CRBP IV* is a common target for the disruption of retinoid signaling pathway in human cancers. However, the exact function of this retinol-binding protein is still not known yet. To elucidate the function of *CRBP IV* in NPC tumorigenesis, depletion of *CRBP IV* expression in an immortalized nasopharyngeal cell line NP69 by siRNA is ongoing.

In this study, we have further confirmed a high frequency of *RAR β* methylation in primary NPC tumors

(78.7%). Our data also demonstrated the relatively common simultaneous inactivation of *CRBPI*, *CRBP IV* , and *RAR β* in NPC cell lines, xenografts, and primary tumors. Although the underlying biologic significance of this observation is largely unknown, the findings may indicate that inactivation of all these genes—*CRBPI*, *CRBP IV* , and *RAR β* —is necessary to completely abolish the retinoid signaling pathway in NPC. Further functional studies to investigate their roles in retinoid signaling in nasopharyngeal epithelial cells are needed. A recent study has also reported the relatively common simultaneous epigenetic inactivation of *CRBPI* and *RAR β* in human cancers [11]. The authors proposed that *CRBPI* may have a function independent of its retinol-binding ability. Nevertheless, these findings indicated that inactivation of the CRBPs, *CRBPI* and *CRBP IV* , as well as loss of *RAR β* , are important in the development of human cancers.

Taken together, in this study, *CRBPI*, *CRBP IV* , and *RAR β* gene silencing by promoter hypermethylation was frequently observed in NPC. The disruption of these genes in the majority of NPC samples may explain the resistance of retinoic acid treatment in this cancer type. Besides, *RAR β* , *CRBPI*, and *CRBP IV* are novel candidate targets involving in aberrant retinoid signaling in human cancers. Our findings first demonstrated that epigenetic inactivation of multiple CRBPs is involved in the tumorigenesis of NPC.

Acknowledgements

This work was carried out within the Hong Kong Cancer Genetics Research Group and was supported by the Kadoorie Charitable Foundations and the Hong Kong Research Grant Council (CUHK 4067/02M, 4071/02M, 410/03M, and HKUST 2/03C).

References

- [1] Blomhoff R, Green MH, Green JB, Berg T, and Norum KR (1991). Vitamin A metabolism: new perspectives on absorption, transport, and storage. *Physiol Rev* **71**, 951–990.
- [2] Newcomer ME (1995). Retinoid binding proteins: structural determinants important for function. *FASEB J* **9**, 229–239.
- [3] Napoli JL (1996). Retinoic acid biosynthesis and metabolism. *FASEB J* **10**, 993–1001.
- [4] Fiorella PD, Giguère V, and Napoli JL (1993). Expression of cellular retinoic acid-binding protein (type II) in *Escherichia coli*: characterization and comparison to cellular retinoic acid-binding protein (type I). *J Biol Chem* **268**, 21545–21552.
- [5] Chambon P (1996). A decade of molecular biology of retinoic acid receptors. *FASEB J* **10**, 940–954.
- [6] Zelent A (1994). Translocation of the RAR alpha locus to the *PML* or *PLZF* gene in acute promyelocytic leukaemia. *Br J Haematol* **86**, 451–460.
- [7] Jing Y, Bleiweiss IJ, Waxman S, Zelent A, and Mira-y-Lopez R (1996). Defective expression of cellular retinol-binding protein type I and retinoic acid receptors α 2, β 2, and γ 2 in human breast cancer cells. *FASEB J* **10**, 1064–1070.
- [8] Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie JM, Hong WK, and Lotan R (1997). Suppression of retinoic acid receptor β in non-small cell lung cancer *in vivo*: implication for lung cancer development. *J Natl Cancer Inst* **89**, 624–629.
- [9] Widschwendter M, Berger J, Hermann M, Müller HM, Amberger A, Zeschknig M, Widschwendter A, Abendstein B, Zeimet AG, Daxenbichler G, and Marth C (2000). Methylation and silencing of the retinoic acid receptor- β 2 gene in breast cancer. *J Natl Cancer Inst* **92**, 826–832.
- [10] Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, and Sacchi N (2000). Evidence of epigenetic changes affecting the

- chromatin state of the retinoic acid receptor β 2 promoter in breast cancer cells. *Oncogene* **19**, 1556–1563.
- [11] Esteller M, Guo M, Moreno V, Peinado MA, Capella G, Galm O, Baylin SB, and Herman JG (2002). Hypermethylation-associated inactivation of the cellular retinol-binding protein 1 gene in human cancer. *Cancer Res* **62**, 5902–5905.
- [12] Lam PK, To EWH, Chan ESY, Liew CT, Lung IWH, and King WK (2001). *In vitro* inhibition of head and neck cancer-cell growth by human recombinant interferon- α and 13-*cis* retinoic acid. *Br J Biomed Sci* **58**, 226–229.
- [13] Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, and Huang DP (2002). Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. *Clin Cancer Res* **8**, 131–137.
- [14] Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ, and Huang DP (2001). High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. *Cancer Res* **61**, 3877–3881.
- [15] Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z, Wong N, Yuen PW, Lo AK, Wong YC, and Huang DP (2002). Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. *Biochim Biophys Acta* **1590**, 150–158.
- [16] Lo KW, Teo PM, Hui AB, To KF, Tsang YS, Chan SY, Mak KF, Lee JC, and Huang DP (2000). High resolution allelotype of microdissected primary nasopharyngeal carcinoma. *Cancer Res* **60**, 3348–3353.
- [17] Herman JG, Graff JR, Myohanen S, Nelkin BD, and Baylin SB (1996). Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci USA* **93**, 9821–9826.
- [18] Noy N (2000). Retinoid-binding proteins: mediators of retinoid action. *Biochem J* **348**, 481–495.
- [19] Ross AC (1993). Overview of retinoid metabolism. *J Nutr* **123**, 346–350.
- [20] Napoli JL (1993). Biosynthesis and metabolism of retinoic acid: roles of CRBP and CRABP in retinoic acid: roles of CRBP and CRABP in retinoic acid homeostasis. *J Nutr* **123**, 362–366.
- [21] Kuppumbatti YS, Bleiweiss IJ, Mandeli JP, Waxman S, and Mira-y-Lopez R (2000). Cellular retinol-binding protein expression and breast cancer. *J Natl Cancer Inst* **92**, 475–480.
- [22] Kuppumbatti YS, Rexer B, Nakajo S, Nakaya K, and Mira-y-Lopez R (2001). CRBP suppresses breast cancer cell survival and anchorage-independent growth. *Oncogene* **20**, 7413–7419.
- [23] Fotti C, Calderone V, Ramazzina I, Zanotti G, and Berni R (2002). Ligand binding and structural analysis of a human putative cellular retinol-binding protein. *J Biol Chem* **277**, 41970–41977.